EDIT
Editas Medicine Inc

17,076
Mkt Cap
$229.02M
Volume
1.78M
52W High
$4.54
52W Low
$0.9101
PE Ratio
-1.24
EDIT Fundamentals
Price
$2.34
Prev Close
$2.35
Open
$2.35
50D MA
$2.09
Beta
2.04
Avg. Volume
1.59M
EPS (Annual)
-$1.80
P/B
8.39
Rev/Employee
$465,747.13
$111.99
Loading...
Loading...
News
all
press releases
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Is Editas Medicine Going to $0?
Key PointsEditas Medicine has been on fire over the trailing-12-month period...
Nasdaq News: Markets·4d ago
News Placeholder
Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401
Editas Medicine (NASDAQ:EDIT) executives outlined the company's in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore...
MarketBeat·6d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Upgraded at JonesTrading
JonesTrading raised shares of Editas Medicine from a "hold" rating to a "buy" rating and set a $8.00 price objective on the stock in a research note on Tuesday...
MarketBeat·11d ago
News Placeholder
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.
Zacks·11d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Receives "Buy" Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $3.50 price target on shares of Editas Medicine in a report on Monday...
MarketBeat·12d ago
News Placeholder
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +77.78% and +280.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Editas Medicine Q4 Earnings Assessment
read more...
Benzinga·12d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) CEO Sells $10,895.88 in Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,394 shares of Editas Medicine stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average...
MarketBeat·16d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,394 shares of the company's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average...
MarketBeat·17d ago
<
1
2
...
>

Latest EDIT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.